Canary Capital has initiated coverage on @NeurotechInt (#ASX: $NTI) with a Strong Buy recommendation and an intrinsic value estimate of $0.155 per share. Based on the share price of $0.013 used in the report, this represents potential upside of approximately 812%. A key takeaway from the report is NTI's progress towards a potentially significant clinical milestone, with its Beyond Harmony Phase III trial now underway. The 200-patient study is evaluating NTI164 for #Autism Spectrum Disorder (#ASD), following positive Phase II/III results that demonstrated improvements in overall illness severity, adaptive functioning and social responsiveness. Canary Capital also highlights the commercial opportunity for NTI164, particularly in Australia, where the company intends to pursue initial commercialisation before exploring licensing opportunities in larger international markets. Canary's valuation is based solely on the Australian ASD opportunity and does not include potential value from Neurotech's other programs in Rett syndrome, PANS/PANDAS and cerebral palsy, or from international markets. While clinical and regulatory risks remain, Canary Capital identifies the Phase III trial results as a key catalyst for the company's future valuation. #Healthcare #AutismResearch #Neuroinflammation

"NTI has proven in Phase II trials that its product is safer and just as effective as Neuren’s product for treating Rett Syndrome... With $11.6M in the bank and solid clinical data, NTI is ready to find partners that can take its product to the next level." @NeurotechInt (#ASX: $NTI) is entering a pivotal phase, transitioning from clinical trials to securing strategic partnerships. With positive Phase II results for NTI164 across three neurological disorders, NTI is now well-positioned to seek global partners to advance its product into the US, Europe, and Asia. As the #biotech industry witnesses billion-dollar deals, NTI's progress could lead to significant market opportunities. Read the latest Investment Memo by @NextInvestors for more info: ⬇️ nextinvestors.com/quick-take… #NeurotechInternational #Biotech #ASX #InvestmentNews #ClinicalTrials #NeurologicalDisorders #NTI164 #DealMaking #PharmaPartnerships #OrphanDrug #Neuren $NEU